In The Aftermath Of The Children's Accountless Kidney Accident Incident, The Sirop Praxion Drug Was Withdrawn From Pasaran

Anti-Preventional fever reduction sirop drug

JAKARTA - PT Pharos Indonesia made voluntary withdrawals of products or voluntary recall of fever-decreasing sirop drugs, Praxion as the responsibility of the pharmaceutical industry for incidents of pediatric patients experiencing atypical progressive acute kidney failure (GGAPA).

Based on the company's official press release received in Jakarta, Tuesday afternoon, PT Pharos Indonesia conducted a re-examination of product security in an internal laboratory. The test was carried out in accordance with the Indonesian Farmakope rule edition VI supplement II.

"The results of this internal examination show that the product still meets the specifications of Indonesian Farmakope," said PT Pharos Indonesia Director of Corporate Communication Ida Nurtika.

PT Pharos Indonesia expressed concern over the report. Voluntary withdrawal of products from the market is taken as a precautionary measure to ensure the safety of consumers.

"As a precautionary measure, PT Pharos Indonesia has listed Praxion products from related batches as the responsibility of the pharmaceutical industry," he said.

He said PT Pharos Indonesia had asked all distribution and sales partners not to temporarily sell Praxion products until further notice.

To ensure product quality and safety, PT Pharos Indonesia conducted examinations on three accredited external laboratory facilities. The results of the examination will be obtained in the next few days.

To strengthen data, PT Pharos Indonesia actively collects product samples from pharmacy networks for intensive quality and safety checks.

"Praxions have been produced according to the standard Good Manufacturing Practices (CPOB)," he said.

PT Pharos Indonesia fully supports the efforts of the Ministry of Health and the Food and Drug Supervisory Agency (BPOM) to investigate the matter.

PT Pharos has opened communication for the public about Praxion products through customercare @pharos.co.id.

Meanwhile, from observations through the e-commerce market network, today, it appears that Praxion's sirop drug is no longer being marketed. Previously, the drug sales link was still displayed on a number of e-commerce services on Monday.

BPOM has issued orders for withdrawal of the drug from all networks of health care facilities, including pharmacies and hospitals.

The Ministry of Health has also issued an appeal to all health workers to be aware of symptoms that arise in acute kidney disorders in all health facilities.

"The specific symptoms that we detected from one suspected patient in Jakarta were difficult to breed before finally having a fever," said Head of the Communication and Public Service Bureau of the Indonesian Ministry of Health, Siti Nadia Tarmizi.

Nadia also appealed to the public to avoid buying sirop drugs independently. If you find symptoms, the patient is asked to be taken to the nearest health care facility for early treatment.

Previously, it was reported that two DKI Jakarta residents aged 1 and 7 were reported to have acute kidney problems. One of them was reported to have died a week ago, while one suspected patient was still undergoing intensive treatment at the Jakarta RSCM.